M e c h a n i c a l heart valves (MHVs) are highly thrombogenic, and a pregnancy-induced procoagulant status increases the risk of MHV thrombosis up to 10%. Hence, optimal anticoagulation is of particular importance in pregnant women with a MHV. The optimal type, dose, and route of anticoagulation therapy, however, remains unclear. Some of the proposed regimens include unfractionated heparin (UFH), low molecular weight heparin (LMWH), and vitamin-K antagonists (VKA). Each of these may be used either alone throughout the pregnancy, or in combination, with 1 regimen administered in the first trimester and another for the remainder of the pregnancy. Regardless of the therapy used, both the mother and the fetus remain at risk of adverse outcomes. [1] Although the most recent guidelines recommend the use of LMWH with anti-factor Xa follow-up in the first trimester, the risk of prosthetic valve thrombosis (PVT) is still a concern, as described in the following case series.
CASE REPORT
Case 1 -A 36-year-old female who was 27 weeks pregnant presented at the emergency department with recently progressive dyspnea and fatigue. She had undergone aortic valve replacement (AVR) (No.19; St. Jude Medical, Inc., St. Paul, MN, USA) for a bicuspid aortic valve 8 years prior and did not have any other known disease. Following the surgical intervention, the patient self-administered VKA, but since becoming pregnant (5 weeks), the warfarin dosage had been discontinued for the first trimester and enoxaparin sodium (60 mg; 6000 anti-Xa IU-60 (Fig. 1a) . After transesophageal echocardiography (TEE) disclosed an obstructive prosthetic valve thrombosis (PVT) with a mobile portion of 8 mm and a total area of 0.83 cm 2 ( Fig. 1b and Video 2), an ultra-slow infusion (25 hours) of low-dose (25 mg) tissue plasminogen activator (t-PA) was administered. Repeat TTE and TEE revealed that the thrombus had been eliminated and there was a normalization of the transaortic gradient (65 mm Hg (peak)/38 mm Hg (mean) (Fig. 1c, d and Video 3, 4). The patient underwent anticoagulation with VKA with a target international normalized ratio (INR) of between 2.5 and 4 for the rest of the pregnancy. At the 37 th week of pregnancy, the use of warfarin was again eliminated and replaced with UFH until the day of a planned caesarean section. The patient gave birth to a healthy infant and both the mother and the baby continued to do well at monthly follow-ups.
Case 2 -A 27-year-old female in the first trimester of her pregnancy (6 weeks) visited the clinic for a regular Immediately after recognition of the pregnancy, warfarin was discontinued for the first trimester and enoxaparin sodium (60 mg; enoxaparin 6000 antiXa IU-60 mg/0.6 mL) twice daily was prescribed by her primary care physician. TTE and TEE were performed at the sixth week of pregnancy (as per the routine follow-up protocol at the institution for pregnant women with prosthetic valves, baseline TTE and TEE were performed and repeated after the completion of ), an ultra-slow infusion of t-PA (25 hours) was provided at a low dose (25 mg). After the thrombolytic therapy, TEE was performed once more, and a detailed evaluation of the mitral mechanical valve showed near-complete lysis of the thrombus. At the 37 th week of pregnancy, warfarin was replaced with UFH. At 39 th week, the patient delivered a healthy baby via planned cesarean section.
Case 3 -A 26-year-old woman who was 8 weeks pregnant with a history of an ischemic cerebrovascular event 1 week prior was referred to the clinic for further examination. She had undergone AVR (No. 23; St. Jude Medical Inc., St. Paul, MN, USA) for rheumatic aortic regurgitation 8 years earlier. Immediately after detection of beta-human chorionic gonadotropin in the blood, warfarin use was discontinued and enoxaparin sodium (60 mg; 6000 anti-Xa IU-60 mg/0.6 mL) twice daily was prescribed by her gynecologist for the first trimester. She had anti-factor Xa levels of between 0.80 and 0.93 IU/mL (Table  1) . A bedside TTE demonstrated normal transaortic gradients of 38 mm Hg (peak)/27 mm Hg (mean). TEE was performed and a nonobstructive PVT on the aortic side with mobile sections of 7 mm and 11 mm in diameter and a total area of 0.45 cm 2 was noted. Intensive anticoagulation therapy with UFH was initiated with a target activated partial thromboplastin time of between 50 and 70 seconds with weekly TEE reassessment. After 2 weeks, the TEE showed a significant decrease in thrombus burden with a residual small thrombus of 0.07 cm 2 ( Fig. 2d) . At the fourth week of UFH treatment, no residual thrombus was observed. Warfarin use was reinstituted (10 mg/day) once the patient reached the 12 th week of pregnancy, with a target INR of 2.5 to 4. At the 37 th week of gestation, the warfarin was replaced with UFH until the day of a planned caesarean section. After a successful delivery, warfarin therapy was re-initiated. Both the patient and the baby remained well during more than 2 years of follow-up.
DISCUSSION
We report 3 cases of PVT occurring despite treatment with LMWH and regular anti-factor Xa follow-up. One of these patients had an obstructive PVT, while 2 were cases of a relatively large, nonobstructive PVT. Two were treated with low-dose ultra-slow thrombolytic therapy, a novel treatment method according to recent studies in the literature. [2, 3] The patient in case 3 developed nonobstructive PVT, which was treated with UFH therapy. In such cases, administration of anticoagulants other than a VKA, such as UFH and LMWH, has long been recommended due to concerns about fetotoxicity. Of note, all 3 of these patients were followed with optimal monitoring for anti-factor Xa during pregnancy. Current evidence indicates that the administration of a VKA throughout pregnancy is the most favorable approach, with a PVT risk as low as 3.9%. However, a VKA crosses the placental barrier, and at high doses (i.e., >5 mg) can cause embryopathy when used in the first trimester, as well as other adverse fetal outcomes beyond the first trimester. [1, 4] But this risk has been reported to be as low as 0% to 2.6% at low doses. Therefore, it is reasonable to continue VKA treatment throughout a pregnancy if the required dose before pregnancy is low, as per up-to-date guideline recommendations. The most recent meta-analysis examining maternal and fetal outcomes of anticoagulated pregnant women with a MHV included 800 pregnancies and 18 publications, and a warfarin dose of <5 mg did not significantly impact fetal risk. [1, 5] On the other hand, although UFH during the first trimester is safe for the fetus, it is associated with an unacceptable PVT risk. The highest risk strategy in terms of PVT should be noted, which is as much as 33% when pregnant patients are continuously administered with adjusted-dose or low-dose UFH. [6] LMWHs may display more potent anticoagulation in comparison with UFH since they inhibit both factor II and Xa. LMWHs are more bioavailable when administered subcutaneously. Moreover, although LMWHs are also safe in terms of fetal outcomes, the risk of PVT without anti-factor Xa monitoring is still high. [7, 8] Current guidelines [9] and most recent expert opinions [10] [11] [12] recommend the use of LMWH with a target peak anti-factor Xa of between 0.8 and 1.2 IU/mL as the most favorable approach in terms of risk-benefit ratio. For LMWH administration over the course of a pregnancy, the risk of valve thrombus is about 7.1% to 12.3%, according to research with sample groups and including examination of anti-factor Xa levels. [13, 14] However, there is ongoing debate about whether peak or trough levels should be used. A recent study by Goland et al. [15] demonstrated that routine measurement of the trough anti-factor Xa level may be necessary in women with MHVs treated with LMWH during pregnancy to assure an adequate level of anticoagulation. Although recent reports and guidelines recommend LMWH in terms of fetal safety, this case series demonstrates that LMWH with adequate peak anti-factor Xa follow-up is not devoid of PVT risk. Furthermore, the predictors of PVT risk despite anticoagulation with LMWH are unclear. The so-called risk factors are a history of previous valve thrombosis/embolism, atrial fibrillation, spontaneous echo contrast, left atrial enlargement, and left ventricular dysfunction. For instance, in a pregnant woman with an initial TEE assessment of nonobstructive PVT, complete discontinuation of VKA may be quite unsafe and may predispose the mother to severe adverse events, including valve obstruction and/ or cerebral embolism. Even in a patient who is initially thrombus-free but has a history of previous thromboembolism, it can be argued that discontinuation of VKA and switching the therapy to LMWH does not inspire confidence. Based on this series, considering the development of new PVT in patients without any initial evidence of thrombus, LMWH seems to have the risk of potentially adverse maternal outcomes. Given these rationales, we believe that safer treatment methods other than LMWH with anti-factor Xa follow-up should be developed for pregnant women with a MHV. For such patients, a low dose of VKA can be used in combination with LMWH as a treatment option in order to provide a slight increase in INR and adequate anti-coagulation. The efficacy and safety of such a strategy compared with standard LMWH should be confirmed with findings from large series.
Conclusion
In conclusion, despite the use of LMWH with frequent monitoring of anti-factor Xa activity during the first trimester or throughout pregnancy, the PVT risk is not completely avoidable and more potent anticoagulation regimens without detrimental effects to the fetus should be developed.
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